The global single-cell analysis market size was valued at USD 2.65 billion in 2021, is projected to reach USD 13.63 billion by 2030, and is expected to expand at a CAGR of 17.9% during the forecast period, 2021–2030. The growth of the market is attributed to the increasing prevalence of cancer worldwide and the rapid development of technologies that have cascaded huge investments from life sciences companies and government funding initiatives for research activities.
Single cell analysis discovers unique characteristics of individual cells within a cell population. The study of transcriptomics, metabolomics, proteomics, genomes, and cell interactions at the single cell level is referred to as single cell analysis. Single cell analysis is widely utilized in microbiology, immunology, neurobiology, prenatal diagnosis, embryogenesis, and plant biology. Personalized medicine is manufactured by referring genetic profile of a particular individual to find out the treatment of a disease. Personalized medicine aids in the prevention and diagnosis of the disease for specific individuals. Microfluidic platforms of single-cell analysis allow for precise manipulation by trapping, transporting, and releasing single cells. Microfluidic platforms work at a scale comparable to cell diameter and are suitable for single-cell manipulation. A microfluidic trapping array has the ability to quickly and deterministically trap single cells in densely packed microwells. This trapping array is coupled with the different microfluidic sample processing units with different flow rates for various single-cell analyses, as the single cell trapping efficiency is determined by the channel design of the flow rates. Single cell analysis helps in the treatment of various diseases by giving insights into the needs of individual patients, personalized treatment, and the nature of the disease. Moreover, many people are preferring personalized medicine for themselves. For instance, In July 2021, as per the survey conducted by Dosis, a dosing platform provider, of 1000 people, 85% of patients think that personalized medicine improves care for them and 80% of patients think that personalized medicine is expected to be available for all.
COVID-19 Impact
The COVID-19 pandemic has had a positive impact on the single-cell analysis market, as the pandemic triggered the widespread adoption of single-cell analysis methods in virology research. The covid-19 disease spread across the globe, post its discovery in Wuhan. Coronavirus causes various symptoms in patients. Researchers are utilizing the specimens from COVID-19 biobanks for performing analysis to understand the immune response and the long-term effects of infections. For instance, the researchers from The NHLBI LungMap Consortium and The Human Cell Atlas Lung Biological Network accomplished a single-cell meta-analysis in 1,320,896 cells from 228 humans. The study is conducted to study the entry of genes of SARS-CoV-2 across demographics. Moreover, in January 2021, according to the American Journal of Physiology, single cell analysis through mass cytometry was used to study the changes in the peripheral blood mononuclear cell profiles of COVID-19-infected patients.
Market Dynamics
The report presents a complete market overview, and market dynamics by focusing on the current market trends, existing drivers, growth opportunities, and emerging challenges that shape the outcome or overall performance of the market during the forecast period, 2022 to 2030.
Major Drivers: Rising prevalence of cancer
The important application area of single cell analysis is cancer genomics. GLOBOCAN anticipated that from 19.3 million cases and 10 million cancer deaths in 2020, there will be around 30 million new cases of cancer globally by 2040. Single cell analysis is a crucial component of this study since the frequency of this disease is increasing and there is a need to perform significant research for diagnosis and therapy. The accurate identification of illnesses and the tracking of therapy effectiveness are made possible by the examination of individual cells. Single cell analysis is used to determine DNA composition, count helper T cells, and track the growth of tumor cells in breast cancer and other malignancies.
Current Restraints: High cost of single cell analysis products
The requirement to uphold high standards (the use of pricey, high-grade materials) and adhere to regulatory bodies’ directives drives up the price of single cell biology research. However, budget restrictions make it challenging for universities and research labs to purchase such pricey equipment. The total cost of ownership of these instruments has increased as a result of the maintenance charges as well as a number of other indirect expenses. This is a significant obstacle to the widespread use of flow cytometers and microfluidic devices in both clinical and academia settings.
Market Opportunities: High growth potential of single cell sequencing
Single cell sequencing is regarded as a potent method for locating illness-specific biomarkers to diagnose and track the onset, progression, and patient response to therapy. Companies are concentrating on creating equipment and reagents that are appropriate for single cell sequencers since the single cell analysis technology delivers substantial insights about genetic alterations. Numerous sophisticated single cell analysis instruments are anticipated to be developed and released in the market in the upcoming years because of the great growth potential of this category.
Scope of the Report
The report on the global single-cell analysis market includes an assessment of the market trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Single-cell Analysis Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2021
|
|
Historic Data
|
2019–2020
|
|
Forecast Period
|
2022–2030
|
|
Segmentation
|
Applications (Immunology, Neurology, In-vitro Fertilization, Non-invasive Prenatal Diagnosis, Stem Cell, Cancer, and Others), Workflows (Data Analysis, Downstream Analysis, and Single Cell Isolation & Library Preparation), Products (Instruments [Flow Cytometers, Next Generation Sequencing, PCR Systems, High-content Screening System, Cell Microarrays, Automated Cell Counters, Manual Instruments, Microscopes, Hemocytometers, and Automated Instruments] and Consumables [Assay Kits and Reagents]), and End-users (Biotechnology & Pharmaceutical Companies, Hospitals & Diagnostic Laboratories, and Academic & Research Laboratories)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Illumina Inc.; Merck KGaA; Becton, Dickinson & Company; Fluidigm Corporation; 10x Genomics, Inc.; BGI; Novogene Corporation; Thermo Fisher Scientific Inc.; QIAGEN NV; and Bio-Rad Laboratories Inc.
|
Market Segment Insights
Cancer segment to expand at a considerable CAGR
On the basis of applications, the single-cell analysis market is segmented into immunology, neurology, in-vitro fertilization, non-invasive prenatal diagnosis, stem cell, cancer, and others. The cancer segment is projected to expand at a considerable CAGR during the forecast period, as single-cell analysis is used for the effective diagnosis of cancer cells. The cancer segment accounted large revenue share of over 30.0% in 2021. According to the American Cancer Society, cancer is the common reason for death in the U.S. after heart disease. In 2022, as per the cancer statistics, 1.9 million new cancer cases are anticipated to occur in the U.S. Therefore, the rising cases of cancer and persistent studies and development in this field are expected to propel the market growth. The mutation rates, genetic variation via cell proliferation conditions, and cell types are identified using the single cell analysis technique.
The stem cell segment is anticipated to account for a major market share during the forecast period, owing to the rising demand for stem cell therapies for personalized and regenerative medicines. The usage rates of single-cell analysis techniques are increased, owing to several therapies such as transplants of tissue, organ, and bone marrow, and regeneration of hair. Single-cell analysis methods are widely used in therapeutic and diagnostic applications, owing to the significant number of research activities for evaluating single-cell genomics and proteomics.
Single cell isolation & library preparation segment to hold a significant share of the market
Based on workflows, the market is divided into data analysis, downstream analysis, and single cell isolation & library preparation. The single cell isolation & library preparation segment is expected to hold a significant share of the market in the coming years. The single cell isolation and library preparation accounted for a large revenue share of over 35.0%. Applications of single cell analysis increased the demand for cell isolation and library preparation products including reagents and kits. Key players are offering a range of products for single cell isolation including MACS and FACS for heterogeneous cell suspension, flow cytometry, microdissection of fixed tissue samples, and microfluidics.
The downstream analysis segment accounts for a significant market share, due to the technological advancements during the forecast period. Researchers use important tools for single cell analysis including mass spectrometry, next-generation sequencing for analyzing cellular expressions, and fluorescence in situ hybridization. Moreover, the market is observing rising automation of machines and artificial intelligence for data analysis. Various computational and software methods are being employed owing to their benefits including flexibility, scalability, and high success rates. For instance, there are 1000 single cell RNA analysis tools. the high growth of database tools reflects the availability and interest in SCA technologies, which, in turn, propel the market growth during the forecast period.
Consumables segment to expand at a substantial CAGR
On the basis of products, the single-cell analysis market is segregated into instruments and consumables. The instrument segment is further segregated into flow cytometers, next generation sequencing, PCR systems, high-content screening system, cell microarrays, automated cell counters, manual instruments, microscopes, hemocytometers, and automated instruments. The consumables segment is further categorized into assay kits and reagents. The consumables segment is anticipated to expand at a substantial CAGR during the forecast period, due to the high usability of isolation products, frequent purchase of buffers and reagents, and rising demand for assay kits. The consumable segment accounted for a large market revenue share of over 50.0% in 2021. The segment is growing as a result of a rise in the frequency of the target disorders and the ongoing need for the supplies needed for the tests throughout research experiments. Furthermore, there is a constant need for reagents throughout single cell analysis assays. These reagents are available in a variety of forms, such as cellular markers, phenotyping agents, multicolor cocktails, and probes. The active efforts of scientific organizations have led to the widespread acceptance and acquisition of reagents, which has generated sales on the international market.
The instruments segment is expected to hold a significant share of the market, due to the technically sophisticated analysis choices and their high-end features. The installation of new instruments, and the replacements of outdated instruments-related services are all driving segment growth.
Academic & Research laboratories segment to register considerable market share
Based on end-users, the market is segmented into biotechnology & pharmaceutical companies, hospitals & diagnostic laboratories, and academic & research laboratories. The academic & research laboratories segment is projected to register a considerable share of the market in the coming years, owing to the wide use of single cell analysis technology in research activities. The widespread use of single cell analysis methods in several active scientific studies at numerous institutions in 2021 is expected to drive segment growth. Another important aspect influencing the market is the development of spatial genomics. Which speeds single cell analysis in research operations. The industry is also being driven by the development of new tools to address research limitations. For instance, in June 2022, researchers at Stony Brook University in New York created the single cell cyclic multiplex in situ tagging (CycMIST) technology, a new biomedical research tool. This technology enables researchers to evaluate functional proteins in a single cell and advance the disciplines of diagnosis and discovery.
Single cell analysis utilization by biotechnology and pharmaceutical industries has expanded as a result of technological advancements including the use of microfluidics for the creation of cell and gene treatments. the market is anticipated to be further propelled by the growing use of multi-omics in medication development research. Many businesses have made investments in genomics to gain access to various genome datasets. For instance, Boehringer Ingelheim and Lifebit, a big data startup located in the UK, established a partnership in March 2022. The Collaboration is projected to employ Lifebit’s Cloud OS, the first federated genomics platform, to create a data analytics infrastructure for Boehringer. This infrastructure uses disease-related information from biobanks to produce new medications. In 2021, Boehringer joined forces with Lifebit’s REAL platform to hasten the diagnosis and monitoring of the disease pandemic.
North America is anticipated to constitute a key market share
In terms of regions, the single-cell analysis market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to constitute a key share of the market during the forecast period, owing to multiple government funding programs, and the fast adoption of novel analytical tools and techniques, increasing awareness regarding personal healthcare and related expenditure. The growth of the market in North America is due to the U.S. For instance, metabolomics research is supported by the American NIH (National Institutes of Health) through its common Fund programs. The NIH has used the same money to support the single cell analysis program. The existence of important market participants, the desire for tailored medications, and the region’s exceptional healthcare infrastructure are some of the main drivers of regional growth.
The market in the Asia Pacific is anticipated to expand at a rapid pace during the forecast period, due to the rising geriatric population and growing medical industry. The increasing geriatric population has resulted in fueling the demand for cutting-edge diagnostic tools in the emerging economies of the Asia Pacific. This area has experienced substantial expansion as a result of concentrated efforts and outsourcing.
Segments
The global single-cell analysis market has been segmented on the basis of
Applications
- Immunology
- Neurology
- In-vitro Fertilization
- Non-invasive Prenatal Diagnosis
- Stem Cell
- Cancer
- Others
Workflows
- Data Analysis
- Downstream Analysis
- Single Cell Isolation & Library Preparation
Products
- Instruments
- Flow Cytometers
- Next Generation Sequencing
- PCR Systems
- High-content Screening System
- Cell Microarrays
- Automated Cell Counters
- Manual Instruments
- Microscopes
- Hemocytometers
- Automated Instruments
- Consumables
End-users
- Biotechnology & Pharmaceutical Companies
- Hospitals & Diagnostic Laboratories
- Academic & Research Laboratories
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Illumina Inc.
- Merck KGaA
- Becton, Dickinson & Company
- Fluidigm Corporation
- 10x Genomics, Inc.
- BGI
- Novogene Corporation
- Thermo Fisher Scientific Inc.
- QIAGEN NV
- Bio-Rad Laboratories Inc.
Competitive Landscape
Key players competing in the global single-cell analysis market are Illumina Inc.; Merck KGaA; Becton, Dickinson & Company; Fluidigm Corporation; 10x Genomics, Inc.; BGI; Novogene Corporation; Thermo Fisher Scientific Inc.; QIAGEN NV; and Bio-Rad Laboratories Inc.
The market for single cell analysis is expected to expand during the forecast period, due to the rising popularity of single cell analysis techniques for therapeutic and diagnostic applications. The incidence of genetic abnormalities has increased the demand for earlier detection and more effective therapies. Thus, key players now have excellent potential to seize unexplored opportunities. In order to meet customer demand, these young businesses have concentrated on creating cutting-edge items. For instance, SeqWell Inc. announced the release of the PlexWell Single Cell Rapid Kit in February 2021. The kit is anticipated to be utilized for streamlined NGS library preparation and single cell RNA sequencing. In order to increase its footprint outside of the United States, the firm has entered a distribution deal with CELLINK AB in February 2021 for the sale of its goods.
Request For Customization
Enquiry Before Buying
Speak With Analyst
